Factors/drugs | Examples/comments |
Biological characteristics | Advanced age, hypothyroidism, renal dysfunction, hepatic dysfunction, alcohol consumption, metabolic muscle diseases, heavy exercise, surgery, CYP450 polymorphisms |
Drugs that inhibit CYP450 2C9 (affecting fluvastatin metabolism) | Azole antifungals |
Drugs that inhibit CYP450 3A4 (affecting simvastatin, atorvastatin and lovastatin metabolism) | Amiodarone, tricyclic antidepressants, selective serotonin reuptake inhibitors, macrolide antibiotics, HIV protease inhibitors, verapamil/diltiazem, warfarin, grapefruit juice (contains 6′,7′-dihydroxybergamottin), azole antifungals |
Fibrates | Addition of fibrates to statin monotherapy increases the risk of rhabdomyolysis 12-fold. Gemfibrozil appears to carry the highest risk by inhibiting biliary excretion |
CYP450, cytochrome P450.